Integrated Automated Insulin Delivery System Merged by Sequel Med Tech and Senseonics for One-Year Continuous Glucose Monitoring
In a significant move to advance diabetes technology, Sequel Med Tech and Senseonics Holdings have entered into a commercial development agreement to integrate Sequel's twiist Automated Insulin Delivery (AID) system with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system [1]. This strategic partnership is set to create a more effective automated insulin delivery solution, with a planned launch scheduled for Q4 2025.
The integration of twiist AID with Eversense 365 CGM is a key part of Senseonics' strategy for future innovation and market expansion in diabetes technology. The company's recent financial updates indicate strong growth in Eversense 365 patient starts, supporting the broader ecosystem into which this integration will fit [1][2]. This collaboration is poised to unlock new revenue streams and strengthen the positioning of both companies in the competitive AID market.
People living with type 1 diabetes who choose to use twiist will have the flexibility to select from two compatible CGM partners, the Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor. The potential outcomes for people living with diabetes from this integration could include improved glucose control, increased convenience, and greater flexibility in managing their condition.
Senseonics President and CEO Tim Goodnow stated that the collaboration with Sequel marks a significant step forward in transforming diabetes care. He further emphasized that this partnership underscores the companies' shared commitment to simplifying diabetes management and improving quality of life.
Meanwhile, Sequel CEO and Co-Founder Alan Lotvin stated that the partnership aims to deliver flexibility in diabetes management to users. He added that the agreement will provide individuals with type 1 diabetes the option of a one-year CGM system that integrates with the twiist AID System [3].
The collaboration between Sequel Med Tech and Senseonics Holdings is just one of several initiatives aimed at advancing diabetes management technologies. For instance, the collaboration between PharmaSens and SiBionics aims to advance the development of an all-in-one patch pump [4].
In conclusion, the integration of Eversense with twiist is expected to be available in the third quarter of this year, marking a significant milestone in the journey towards more effective diabetes management. This partnership is a testament to the ongoing efforts to improve the lives of people living with diabetes, offering them greater personalization, more choices, and the potential for improved outcomes.
References: [1] Sequel Med Tech and Senseonics Announce Strategic Partnership for Integrated Diabetes Management System. (2025, March 1). BusinessWire. Retrieved from https://www.businesswire.com/news/home/20250301005267/en/Sequel-Med-Tech-and-Senseonics-Announce-Strategic-Partnership-for-Integrated-Diabetes-Management-System [2] Senseonics Reports Fourth Quarter and Full Year 2024 Financial Results. (2025, February 25). GlobeNewswire. Retrieved from https://www.globenewswire.com/news-release/2025/02/25/2382849/0/en/Senseonics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html [3] Sequel Med Tech and Senseonics to Collaborate on Integrated Diabetes Management System. (2025, March 1). Yahoo Finance. Retrieved from https://finance.yahoo.com/news/sequel-med-tech-senseonics-collaborate-002659036.html [4] PharmaSens and SiBionics Announce Collaboration to Develop All-in-One Patch Pump for Diabetes Management. (2024, September 15). PR Newswire. Retrieved from https://www.prnewswire.com/news-releases/pharma-sens-and-sibionics-announce-collaboration-to-develop-all-in-one-patch-pump-for-diabetes-management-301624420.html
The strategic partnership between Sequel Med Tech and Senseonics Holdings is aligning science and healthcare innovation, as they focus on the development of a one-year CGM system that integrates with Sequel's twiist AID system, aiming to enhance fitness-and-exercise and nutrition management for people living with diabetes.
This integration of technology in diabetes management systems is a competitive move in the health-and-wellness sector, highlighting both companies' dedication to improving the quality of life for individuals while expanding into new markets.
